Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
about
Triple negative breast cancer: looking for the missing link between biology and treatmentsPARP inhibitors in the management of breast cancer: current data and future prospectsNovel therapeutic strategies for patients with triple-negative breast cancerIs it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer ModelBetter pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialPredictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Precision medicine in breast cancer: reality or utopia?The best of both worlds - managing the cancer, saving the bone.53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerPrognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysisExome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiencySEOM clinical guidelines in Hereditary Breast and ovarian cancer.Potential options for managing LOX+ ER- breast cancer patientsPARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Advances in PARP inhibitors for the treatment of breast cancer.Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.Biology and Management of Patients With Triple-Negative Breast Cancer.Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).The Changing Landscape of Breast Cancer: How Biology Drives Therapy.Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging.Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
P2860
Q26783122-EE1FA7ED-B763-43B8-B8DB-D524848AD5A4Q26798352-025D35C0-98A8-4567-BD78-4EAA6485616FQ28067436-06631CB3-6F49-4E46-9CA0-D9B46DC57403Q28073673-7561918E-0FF0-479E-8A23-4FD50746A79CQ28085062-4366C6E3-767F-46EA-BD74-63E12966F3BAQ28550119-6E46F31C-9826-48FE-B572-8D0D0EA4B3C9Q33434092-79D780E8-B70F-4E5A-B10F-A46D40B46353Q33441772-7FCF3EC0-6A96-4D1F-BEAF-02EB3BACD449Q33769821-4E104C07-3527-4212-981F-18C098C5DC2BQ33809114-62C9230A-7BE0-4B57-9983-97DEB5DAD33CQ33920055-72333662-3041-4467-BDD4-4B395AABC4FFQ36129160-6714BEB7-8498-44AE-A6D9-B93EE48F208BQ36224769-B0B7B6FF-48C8-4269-B813-7CFB4FFDC810Q36284245-14294832-B2DA-4CBA-80D1-587EDB193808Q36392466-0428CA8D-E395-4B50-82B5-1C51A53BF022Q36400244-4A210F2B-A958-47C3-8A3B-756D17791DC2Q37362796-725C7919-B534-4969-B5A4-8968141BC8C3Q37607283-EA5694FF-924A-49A1-8440-565A93746E43Q38612128-16641D17-6646-4B31-848B-EBF53D2858EEQ38735426-9D89AE83-BED6-4B64-940D-CF76528C9B3AQ38756892-7E855F48-91B3-4A13-AC37-FF6E5ACD8781Q38780469-F65D38D8-E405-4930-BE17-DAA5190D2E0CQ38893074-9065FDC6-D40E-4302-A889-CE2483C28D58Q39428059-B8D2F653-C7F2-42C4-9FDC-9E4AD2D75EADQ39683758-D0097E13-FA7E-490A-A9C0-3F6179B3A4BDQ40640808-88E4F645-ABB0-476B-BFDE-5253DBBF7C6BQ41719274-6F8F08AC-B30B-486A-A895-21E9F0F0D261Q41747966-BF961D87-2B04-4321-BD07-93455788E195Q42261796-72F43D8E-E3DE-422C-9946-D2B21DCE9B03Q42274807-0818E148-C497-410B-9E8A-BEC5E1CC7751Q45943928-833A7A4C-5386-4C70-974C-4CF1AE7C3E18Q46251266-8A32C72C-C39C-419B-ADFA-6C16D7EFA900Q46354502-A9ADF7E6-C17B-4CB7-9A1E-8028181200BDQ47107372-B4FF95BF-0805-4560-BE2E-24CA3E68B80DQ47185834-77CC3C10-F7FB-417B-BEB5-5AEDA2A72300Q47304779-F2AC3320-C41A-47EF-8673-2FBC85DF3AB2Q47788774-32C80B01-C6A2-4E72-BD1A-EBE34F36EF65Q48118236-10FB5B43-661C-43E9-BFF6-58D2F75CEBDEQ48148198-4FF39268-3671-4F44-A3FF-9EB88EF0038FQ49303842-DC2D8ACA-B3EB-4D32-811A-86704B49CD4B
P2860
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase II Study of Gemcitabine, ...... nomic Instability: PrECOG 0105
@ast
Phase II Study of Gemcitabine, ...... nomic Instability: PrECOG 0105
@en
type
label
Phase II Study of Gemcitabine, ...... nomic Instability: PrECOG 0105
@ast
Phase II Study of Gemcitabine, ...... nomic Instability: PrECOG 0105
@en
prefLabel
Phase II Study of Gemcitabine, ...... nomic Instability: PrECOG 0105
@ast
Phase II Study of Gemcitabine, ...... nomic Instability: PrECOG 0105
@en
P2093
P2860
P356
P1476
Phase II Study of Gemcitabine, ...... nomic Instability: PrECOG 0105
@en
P2093
Allison W Kurian
Anne-Renee Hartman
Barbara Haley
Bobbie Head
Elizabeth A Schackmann
Irene L Wapnir
Jafi A Lipson
Joseph A Sparano
Judith Manola
Julia E Reid
P2860
P304
P356
10.1200/JCO.2014.57.0085
P407
P50
P577
2015-04-06T00:00:00Z